Poor interim statistical analysis of a Phase III trial of Provenge in prostate cancer patients caused Seattle-based Dendreon Corp.'s stock to dive Friday.
Poor interim statistical analysis of a Phase III trial of Provenge in prostate cancer patients caused Seattle-based Dendreon Corp.'s stock to dive Friday.
Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product.
Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product.
